IO Biotech, Inc. Announces Pricing of Initial Public Offering

Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology.

Read the full Press Release here